InvestorsHub Logo
Followers 58
Posts 10138
Boards Moderated 1
Alias Born 09/21/2016

Re: sokol post# 420164

Tuesday, 06/27/2023 10:41:58 AM

Tuesday, June 27, 2023 10:41:58 AM

Post# of 461946
As discussed here on AVXL board, it looks like the AVXL TRIFECTA is a good candidate for demonstrating how this process will work. Start with AVXL DB -trial data and results to date...quickly publish strong trial results to date (lead w/ PD-OLE) , followed then by RSD and AD.

BTW, this could be published any time SOON. IMO. This is A (THE) plan , followed by YUGE explosion in AVXL SP. ...BYE BYE BP.

NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, and Partex N.V. Group (“Partex”), the first Data-to-Drugs digital pharma platform, today announced a strategic partnership with the overall ambition to reshape the future of the biopharma business model.

By combining Anavex's innovative small molecule precision medicine drug development platform and Partex's disruptive approach of Artificial Intelligence (AI) enabled drug development and healthcare sales marketing, this collaboration is intended to drive efficiency, effectiveness, and innovation across the value chain with patient-centric focus at every step.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News